INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 198 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2019. The put-call ratio across all filers is 1.15 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $475 | +101.3% | 25,642 | +45.6% | 0.05% | +88.0% |
| Q1 2023 | $236 | -99.9% | 17,609 | -10.4% | 0.02% | 0.0% |
| Q3 2022 | $274,000 | -0.4% | 19,656 | +64.9% | 0.02% | +31.6% |
| Q1 2021 | $275,000 | +12.2% | 11,921 | +20.3% | 0.02% | -26.9% |
| Q4 2020 | $245,000 | -79.6% | 9,911 | -60.4% | 0.03% | -81.3% |
| Q2 2020 | $1,199,000 | +391.4% | 25,025 | +580.0% | 0.14% | +631.6% |
| Q3 2019 | $244,000 | -32.0% | 3,680 | +14.7% | 0.02% | -5.0% |
| Q1 2019 | $359,000 | -33.3% | 3,209 | -39.9% | 0.02% | -31.0% |
| Q4 2018 | $538,000 | +142.3% | 5,342 | +101.5% | 0.03% | +190.0% |
| Q2 2018 | $222,000 | -5.1% | 2,651 | -33.8% | 0.01% | -16.7% |
| Q4 2017 | $234,000 | -33.5% | 4,003 | +174.7% | 0.01% | -61.3% |
| Q2 2015 | $352,000 | – | 1,457 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |